文献速递炎症性肠病

托法替布诱导治疗可在3天内减轻溃疡性结肠炎患者症状

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-09-10

该研究是对两项3期诱导治疗试验(OCTAVE Induction 1和2)的事后分析,纳入中重度活动性溃疡性结肠炎患者,接受托法替布10 mg每日两次(n=905)或安慰剂(n=234)治疗8周。结果显示,治疗第3天托法替布组在排便频率子评分、每日排便总次数和直肠出血子评分的下降幅度均显著大于安慰剂组,且各亚组效果一致。

要点

  • 第3天托法替布组排便频率子评分较基线下降幅度显著大于安慰剂组。
  • 第3天托法替布组直肠出血子评分较基线下降幅度显著大于安慰剂组。
  • 在既往抗TNF治疗失败等各亚组中均观察到托法替布的一致效果。

核心结论

  • 在中重度活动性溃疡性结肠炎患者中,托法替布诱导治疗较安慰剂在3天内显著改善症状,提示该药起效迅速。

研究设计与样本

  • 对两项3期诱导治疗试验(OCTAVE Induction 1和2)的事后分析,患者接受托法替布10 mg每日两次(n=905)或安慰剂(n=234)治疗8周。
  • 纳入中重度活动性溃疡性结肠炎患者,对糖皮质激素、硫嘌呤类和/或肿瘤坏死因子拮抗剂不耐受或治疗失败。
  • 使用治疗前15天的日记数据计算每日Mayo排便频率子评分和直肠出血子评分。

主要发现

  • 第3天排便频率子评分较基线平均变化:托法替布组-0.27 vs 安慰剂组-0.11(P < .01)。
  • 第3天每日排便总次数较基线平均变化:托法替布组-1.06 vs 安慰剂组-0.27(P < .0001)。
  • 第3天直肠出血子评分较基线平均变化:托法替布组-0.30 vs 安慰剂组-0.14(P < .01)。
  • 第3天排便频率子评分较基线下降≥1分的患者比例:托法替布组241/837(28.8%)vs 安慰剂组39/218(17.9%)(P < .01)。
  • 第3天直肠出血子评分较基线下降≥1分的患者比例:托法替布组266/830(32.0%)vs 安慰剂组43/214(20.1%)(P < .01)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tofacitinib is an oral, small molecule inhibitor of JAK for the treatment of ulcerative colitis (UC). We evaluated the onset of symptom improvement in post-hoc analyses of data from 2 phase 3 trials of induction therapy with tofacitinib in patients with UC (OCTAVE Induction 1 and 2). METHODS: The studies comprised patients with moderate to severe active UC who were intolerant to, or failed by previous treatment with, corticosteroids, thiopurines, and/or tumor necrosis factor (TNF) antagonists. Patients received tofacitinib (10 mg twice daily, n = 905) or placebo (n = 234) for 8 weeks. Daily Mayo stool frequency and rectal bleeding subscores were calculated using diary data from the first 15 days of therapy. We analyzed data from subgroups including failure of prior anti-TNF therapy, baseline corticosteroid use, and baseline serum levels of C-reactive protein. RESULTS: Mean changes were significantly greater in patients given tofacitinib vs placebo in reductions from baseline stool frequency subscore (tofacitinib: -0.27 vs placebo: -0.11; P < .01), total number of daily bowel movements (-1.06 vs -0.27; P < .0001), and rectal bleeding subscore (-0.30 vs -0.14; P < .01) by day 3. Compared with placebo, more tofacitinib-treated patients had reductions from baseline in stool frequency subscore (by ≥1 point for tofacitinib, 241/837, 28.8% vs placebo, 39/218, 17.9%) (P < .01) and rectal bleeding subscore (by ≥1 point for tofacitinib, 266/830, 32.0% vs placebo, 43/214, 20.1%) (P < .01) by day 3. A consistent effect of tofacitinib was observed in all subgroups. CONCLUSIONS: In a post-hoc analysis of data from phase 3 trials of induction therapy with tofacitinib in patients with UC, we found significant improvements in symptoms among patients given tofacitinib compared with placebo within 3 days. These findings indicate the rapid onset of effect of this drug in patients with UC. ClinicalTrials.gov no: NCT01465763 and NCT01458951.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hanauer S, Panaccione R, Danese S, et al. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018. PMID: 30012431. doi:10.1016/j.cgh.2018.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。